A Phase 1 interventional study of LY3484356 in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 19 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 52nd largest by enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2021, is one of 17 in phase 1, and was the 74th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, France and 4 more countries
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 16 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 138 across the 80 interventional studies. Of the 61 that completed or were terminated, 40 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Breast Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05514054Phase 3Eli Lilly and CompanyA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg LY3484356 administered orally once daily for 15 days
Drug: LY3484356
Participants received 400 mg LY3484356 administered orally once daily for 15 days
Drug: LY3484356
Participants received 800 mg LY3484356 administered orally once daily for 15 days
Drug: LY3484356
Administered orally.
Also known as: Imlunestrant
Percent Change From Baseline in Estrogen Receptor (ER) Expression
Tumor tissue collected by biopsy is used to determine ER expression. ER expression is measured by immunohistochemistry (IHC) and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total ER H-score ranged from 0 to 300, where a higher score indicated stronger ER expression. Percent change in ER expression was defined as 100\*(ER expression on-treatment - ER expression pre-treatment)/(ER expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(ER expression on-treatment/ER expression pre-treatment).
Time frame: Baseline, Day 15
Percent Change From Baseline in Ki-67
Tumor tissue collected by biopsy is used to determine Ki-67 expression. It is measured by IHC and the Ki-67 index is defined as the percent of cells staining positive by validated central assay. Percent change in Ki-67 index was defined as 100\*(Ki-67 index on-treatment - Ki-67 index pre-treatment)/(Ki-67 index pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(Ki-67 index on-treatment/Ki-67 index pre-treatment).
Time frame: Baseline, Day 15
Percent Change From Baseline in Progesterone Receptor (PR) Expression
Tumor tissue collected by biopsy is used to determine PR expression. PR expression is measured by IHC and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total PR H-score ranged from 0 to 300, where a higher score indicated stronger PR expression. Percent change in PR expression was defined as 100\*(PR expression on-treatment - PR expression pre-treatment)/(PR expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(PR expression on-treatment/PR expression pre-treatment).
Time frame: Baseline, Day 15
Pharmacokinetics (PK): Plasma Concentration of LY3484356
Plasma Concentration of LY3484356 evaluated using sparse sampling methodology
Time frame: Day 1: 3.5 hours (h) postdose; Day 8: Predose; Day 8: 3.5 h postdose
| Milestone | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 |
|---|---|---|---|
| Started | 28 | 30 | 29 |
| Received at least one dose of study drug | 28 | 30 | 28 |
| Completed | 27 | 30 | 26 |
| Not completed | 1 | 0 | 3 |
| Withdrew: Protocol deviation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 |
Tumor tissue collected by biopsy is used to determine ER expression. ER expression is measured by immunohistochemistry (IHC) and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total ER H-score ranged from 0 to 300, where a higher score indicated stronger ER expression. Percent change in ER expression was defined as 100\*(ER expression on-treatment - ER expression pre-treatment)/(ER expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(ER expression on-treatment/ER expression pre-treatment).
| percent change | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 |
|---|---|---|---|
| Percent Change From Baseline in Estrogen Receptor (ER) Expression | -88.89 (-95.62 to -71.85) | -81.50 (-91.34 to -60.47) | -70.13 (-78.38 to -58.75) |
Tumor tissue collected by biopsy is used to determine Ki-67 expression. It is measured by IHC and the Ki-67 index is defined as the percent of cells staining positive by validated central assay. Percent change in Ki-67 index was defined as 100\*(Ki-67 index on-treatment - Ki-67 index pre-treatment)/(Ki-67 index pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(Ki-67 index on-treatment/Ki-67 index pre-treatment).
| percent change | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 |
|---|---|---|---|
| Percent Change From Baseline in Ki-67 | -68.56 (-78.71 to -53.59) | -70.61 (-80.04 to -56.73) | -72.28 (-81.22 to -59.09) |
Tumor tissue collected by biopsy is used to determine PR expression. PR expression is measured by IHC and quantified by H-score. The H-score was calculated as the sum of multiplying the tumor cell ER staining intensity level 0 to 3 (0=none, 1=low, 2=moderate, 3=high) by the percentage (0 to 100) of cells at each intensity. Total PR H-score ranged from 0 to 300, where a higher score indicated stronger PR expression. Percent change in PR expression was defined as 100\*(PR expression on-treatment - PR expression pre-treatment)/(PR expression pre-treatment). Geometric mean percent change and 90 percent (%) confidence interval for percent change were obtained from a t-test of the log ratio i.e. log(PR expression on-treatment/PR expression pre-treatment).
| percent change | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 |
|---|---|---|---|
| Percent Change From Baseline in Progesterone Receptor (PR) Expression | -85.44 (-96.61 to -37.36) | -75.56 (-90.33 to -38.20) | -82.01 (-91.98 to -59.66) |
Plasma Concentration of LY3484356 evaluated using sparse sampling methodology
| nanograms/milliliter (ng/mL) | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 |
|---|---|---|---|
| Day 1 (3.5 h Postdose) | 25.3 ± 74 | 86.9 ± 82 | 106 ± 107 |
| Day 8 (Predose) | 33.0 ± 70 | 74.3 ± 77 | 99.6 ± 87 |
| Day 8 (3.5 h Postdose) | 55.2 ± 58 | 120 ± 63 | 225 ± 77 |
Collected over Baseline until end of follow-up (up to 63 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg LY3484356 | 0/28 (0%) | 1/28 (3.6%) | 15/28 (53.6%) |
| 400 mg LY3484356 | 0/30 (0%) | 2/30 (6.7%) | 12/30 (40%) |
| 800 mg LY3484356 | 0/28 (0%) | 1/28 (3.6%) | 15/28 (53.6%) |
| Event | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 |
|---|---|---|---|
| Post procedural haematomaInjury, poisoning and procedural complications | 0/28 | 2/30 | 0/28 |
| DiverticulitisInfections and infestations | 0/28 | 0/30 | 1/28 |
| MastitisInfections and infestations | 1/28 | 0/30 | 0/28 |
| Wound dehiscenceInjury, poisoning and procedural complications | 1/28 | 0/30 | 0/28 |
| Event | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/28 | 3/30 | 9/28 |
| NauseaGastrointestinal disorders | 3/28 | 1/30 | 4/28 |
| Hot flushVascular disorders | 4/28 | 2/30 | 2/28 |
| AstheniaGeneral disorders | 0/28 | 4/30 | 1/28 |
| LeukopeniaBlood and lymphatic system disorders | 3/28 | 0/30 | 0/28 |
| FatigueGeneral disorders | 2/28 | 2/30 | 3/28 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/28 | 1/30 | 2/28 |
| DizzinessNervous system disorders | 2/28 | 0/30 | 0/28 |
| HeadacheNervous system disorders | 2/28 | 2/30 | 2/28 |
| Breast painReproductive system and breast disorders | 2/28 | 2/30 | 2/28 |
All enrolled participants who received at least one dose of study drug.
| Age, Continuous(years) | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 | Total |
|---|---|---|---|---|
| Median | 63.0 (50 to 74) | 63.5 (50 to 83) | 64.0 (50 to 83) | 63.5 (50 to 83) |
| Sex: Female, Male(Participants) | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 | Total |
|---|---|---|---|---|
| Female | 28 | 30 | 28 | 86 |
| Male | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 27 | 27 | 23 | 77 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 5 | 8 |
| Region of Enrollment(Participants) | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 | Total |
|---|---|---|---|---|
| Spain | 6 | 13 | 9 | 28 |
| Belgium | 6 | 6 | 7 | 19 |
| Germany | 5 | 7 | 6 | 18 |
| United States | 10 | 3 | 5 | 18 |
| France | 0 | 1 | 1 | 2 |
| United Kingdom | 1 | 0 | 0 | 1 |
| Estrogen Receptor (ER) Expression(H-score) | 200 mg LY3484356 | 400 mg LY3484356 | 800 mg LY3484356 | Total |
|---|---|---|---|---|
| Mean | 256.82 ± 42.33 | 289.81 ± 17.18 | 292.5 ± 13.36 | 281.07 ± 30.35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Nov 2022, 18 months.
Results were first posted in Nov 2025, 3 years after primary completion.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 18 months is below that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imlunestrant